Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Liabilities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Liabilities for 4 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 5.84% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 5.84% year-over-year, with the annual reading at $3.7 million for FY2025, 5.84% down from the prior year.
  • Total Liabilities for Q4 2025 was $3.7 million at bioAffinity Technologies, up from $2.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $16.8 million in Q2 2022, with the low at $775151.0 in Q2 2023.
  • Average Total Liabilities over 4 years is $4.7 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 95.38% in 2023, then surged 315.83% in 2024.
  • Over 4 years, Total Liabilities stood at $1.1 million in 2022, then skyrocketed by 195.63% to $3.4 million in 2023, then rose by 16.2% to $3.9 million in 2024, then decreased by 5.84% to $3.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.7 million, $2.6 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.